)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Crescent Biopharma
Crescent Biopharma (CBIO) investor relations material
Crescent Biopharma Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Strategic focus and portfolio overview
Advancing a matrix portfolio targeting next-gen IO bispecifics, ADCs, and standard of care combinations in thoracic, GI, GynOnc, and head and neck cancers, aiming at a $100B+ market.
CR-001 (PD-1 VEGF bispecific) positioned as a potential best-in-class IO backbone, with additional assets CR-002 (PD-L1 Topo ADC) and CR-003 (integrin beta-6 Topo ADC).
Multi-pronged strategy includes internal pipeline development and external partnerships, notably with Kelun-Biotech.
Kelun-Biotech partnership enables global and China-specific development, with CR-003 in-licensed outside China and CR-001 rights granted to Kelun in Greater China.
$185M PIPE financing in December extends cash runway into 2028, supporting at least four clinical trials in 2024 and data readouts starting Q1 2027.
CR-001 development and differentiation
CR-001 designed to replicate key features of ivonescimab but with improved stability and higher concentration via proprietary engineering.
Global ASCEND phase 1 trial initiated, with sites in the US, EU, and APAC, and parallel development in China by Kelun.
Study design includes tumor type-specific backfill cohorts for efficient data generation in prioritized indications.
Early data in first-line non-small cell lung cancer aims to directly compare with ivonescimab and de-risk later-stage trials.
Robust data set expected by 2027 to inform registration-enabling studies and partnership opportunities.
ADC portfolio and combination strategy
ADCs (CR-002 and CR-003) selected for clinical data support, differentiation via antibody, linker, and payload innovation, and fit within the matrix portfolio.
Each ADC has potential independent value as monotherapy, with comprehensive development across multiple lines and settings.
Combination studies with CR-001 and ADCs to begin in 2024 (with Kelun) and expand in 2027, leveraging both internal and external assets.
Strategy allows flexibility for selective or broad partnerships, depending on data and indication.
Ongoing evaluation of additional ADCs for future portfolio expansion and combination opportunities.
CR-001 global strategy: impact on pharma interest?
Why prioritize PD-L1 and Integrin beta-6 ADCs?
How does CR-001 Phase 1 design de-risk later trials?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Crescent Biopharma earnings date
Q4 202519 Feb, 2026
Crescent Biopharma
Next Crescent Biopharma earnings date
Q4 202519 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage